AstraZeneca strikes $700m deal with Dublin-based Actavis
Drugs giant AstraZeneca is to boost its portfolio with the acquisition of a branded respiratory drug business for up to US $700m (€613m).
The agreement with Dublin-based rival Actavis to buy its respiratory business in North America includes the purchase of inhalation powder Tudorza Pressair, used by sufferers of chronic bronchitis.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





